within Pharmacolibrary.Drugs.ATC.L;

model L01FX26
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.005333333333333333,
    adminDuration  = 600,
    adminMass      = 0.006,
    adminCount     = 1,
    Vd             = 0.0033,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Mirvetuximab soravtansine is an antibody-drug conjugate composed of a folate receptor alpha (FRα) targeting monoclonal antibody linked to the cytotoxic agent DM4 (a maytansinoid tubulin inhibitor). It is used for the treatment of adult patients with folate receptor alpha-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. The drug has received FDA approval for use in these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in adults with advanced solid tumors, including ovarian cancer, receiving intravenous mirvetuximab soravtansine. Parameters represent typical findings in these patient populations.</p><h4>References</h4><ol><li><p>Tu, YP, et al., &amp; Berkenblit, A (2024). Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor-α positive ovarian cancer: The antibody-drug conjugate, payload and metabolite. <i>British journal of clinical pharmacology</i> 90(2) 568–581. DOI:<a href=&quot;https://doi.org/10.1111/bcp.15937&quot;>10.1111/bcp.15937</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37872122/&quot;>https://pubmed.ncbi.nlm.nih.gov/37872122</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01FX26;
